252 related articles for article (PubMed ID: 30827939)
1. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era.
Bakouny Z; Flippot R; Braun DA; Lalani AA; Choueiri TK
Eur Urol Focus; 2020 Jan; 6(1):37-40. PubMed ID: 30827939
[TBL] [Abstract][Full Text] [Related]
2. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
[TBL] [Abstract][Full Text] [Related]
3. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
4. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract][Full Text] [Related]
5. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma.
Anker J; Miller J; Taylor N; Kyprianou N; Tsao CK
Cells; 2021 Nov; 10(11):. PubMed ID: 34831452
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and Radiation Therapy in Renal Cell Carcinoma.
Mollica V; Santoni M; Di Nunno V; Cimadamore A; Cheng L; Lopez-Beltran A; Battelli N; Montironi R; Massari F
Curr Drug Targets; 2020; 21(14):1463-1475. PubMed ID: 32160846
[TBL] [Abstract][Full Text] [Related]
7. [Mode of action, new targets and potential biomarkers in modern immunotherapy].
Bedke J; Stühler V; Todenhöfer T; Stenzl A
Urologe A; 2018 Nov; 57(11):1301-1308. PubMed ID: 30350128
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Renal Cell Carcinoma: The Future Is Now.
Deleuze A; Saout J; Dugay F; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Crouzet L; Laguerre B; Belaud-Rotureau MA; Rioux-Leclercq N; Kammerer-Jacquet SF
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260578
[TBL] [Abstract][Full Text] [Related]
9. Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy.
Ali M; Eid M; Saliby RM; Choi S; McKay RR; Siva S; Braun DA; Chen YW
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438658. PubMed ID: 38875505
[TBL] [Abstract][Full Text] [Related]
10. Novel approaches in the therapy of metastatic renal cell carcinoma.
Lam JS; Leppert JT; Belldegrun AS; Figlin RA
World J Urol; 2005 Jul; 23(3):202-12. PubMed ID: 15812574
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma].
Han SC; Yin HQ; Xu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):305-312. PubMed ID: 35538767
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory Therapies for Renal Cell Carcinoma.
Liu M; Wu H; Shangguan D; Jiang Y; Li X; Liu S; Zhou B; Yin T; Gong Z
Protein Pept Lett; 2018; 25(6):534-547. PubMed ID: 29848257
[TBL] [Abstract][Full Text] [Related]
13. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
Braun DA; Bakouny Z; Hirsch L; Flippot R; Van Allen EM; Wu CJ; Choueiri TK
Nat Rev Clin Oncol; 2021 Apr; 18(4):199-214. PubMed ID: 33437048
[TBL] [Abstract][Full Text] [Related]
14. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
15. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
16. Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review.
Hah YS; Koo KC
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923219
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Anselmo Da Costa I; Rausch S; Kruck S; Todenhöfer T; Stenzl A; Bedke J
Expert Rev Anticancer Ther; 2017 Apr; 17(4):357-368. PubMed ID: 28162024
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
Godwin JL; Zibelman M; Plimack ER; Geynisman DM
Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in kidney cancer: the past, present, and future.
Hammers H
Curr Opin Urol; 2016 Nov; 26(6):543-7. PubMed ID: 27533501
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma.
Grünwald V
Oncol Res Treat; 2016; 39(6):353-8. PubMed ID: 27259695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
